IL2 and non-small cell lung carcinoma: A randomized phase II clinical trial in patients with advanced NSCLC expressing mHsp70 demonstrated good tolerability and clinical responses after the i.v. injection of autologous NK cells that had been ex vivo activated with low-dose IL-2 and an Hsp70-derived 14mer peptide (‘TKD’) [34].